Clene (NASDAQ: CLNN) to present at Canaccord Genuity conference, showcasing efforts to treat ALS and MS. Webcast on August 13, 2024. Investors gain valuable insights.
This news matters as it highlights Clene's efforts to develop innovative therapies for neurodegenerative diseases, which could potentially impact the lives of patients with ALS and MS. Investors can gain valuable insights from the presentation at the conference, influencing their investment decisions.
